CANCER
Novel inhibitors of Aurora A kinase
Ref. CRG-0123
A novel series of compounds which specifically inhibit the effects of Aurora A kinase. Tested in vitro and in human cell culture.
Adenovirus for tumor treatment
Ref. CRG-0113
A new conditionally replicating adenovirus containing a promoter that shows high selectivity and antitumoral efficacy in pancreatic tumors and metastases in vivo.
Novel protein complex as a target for cancer treatment
Ref. CRG-0100
New protein-protein interaction implied in key cellular processes related to tumor development.
Mutant TRAIL protein with enhanced cancer treatment properties
Ref. CRG-0032
In silico design and development of a TRAIL protein variant with an increased binding affinity towards the DR4 receptor.
Mutant TRAIL protein with enhanced cancer treatment properties
Ref. CRG-0052
In silico design and development of a TRAIL protein variant with an increased binding affinity towards the DR5 receptor.
Use of CPEB4 for prognosis or diagnosis of pancreatic cancer
Ref. CRG-0322
Novel target with potential interest in pancreatic ductal adenocarcinoma.
DERMATOLOGY
Kit and procedure to determine predisposition of developing psoriasis.
Ref. CRG-0138
Method and kit for microarray comparative genomic hybridization analysis system. The results can predict the predisposition of an individual to develop psoriasis.
HIV/AIDS
Screening method for compounds to reactivate HIV latency stage.
Ref. CRG-0026
Screening method to detect compounds that can inhibit the latency stage of HIV, making antiretroviral therapy more effective.
NEURODEGENERATIVE DISEASES
Transcription repression of CAG repeats in Huntington’s disease.
Ref. CRG-0307
Novel zinc finger proteins (ZFP) that selectively bind and repress the expression of the mutant huntingtin gene. Tested in an R6/2 mouse model of Huntington’s Disease.
Compounds for the treatment of neurodegenerative diseases.
Ref. CRG-0382
A novel target and family of compounds with potential interest in neurodegenerative diseases treatment.
OSTEOPOROSIS
Novel RANKL Antagonists for the treatment of osteoporosis and cancer.
Ref. CRG-0352
Novel strategy for blocking the RANKL/RANK pathway to prevent bone loss and/or tumor infiltration, with potential for the treatment of osteoporosis, diabetes and cancer. The strategy of design of synthetic ligands can be applied to other members of the TNF superfamily for the treatment of inflammatory and autoimmune diseases.
TOOLS AND REAGENTS
P53 zinc finger nucleases optimised by yeast 1-hybrid.
Ref. CRG-0414/A
A novel functional zinc finger nucleases (ZFN) against two DNA sites in the human p53.